תחזית צמיחת רווח נקי למניה לשנה הבאה ImmunityBio (IBRX)

Expectations for ImmunityBio, Inc. (IBRX) EPS growth next year rely on the powerful technological foundation of the company's US laboratories. However, 69.10 becomes the new value for this metric amid high capital burn and FDA regulatory risks. The business is currently focusing on establishing a distribution network for its first drug, completely ruling out merger deals with other players.

This indicator reflects the daily aggregation of expert expectations regarding net profit growth rates, allowing for a correlation between the current share price of ImmunityBio, Inc. (IBRX) and its future returns. By analyzing the consensus for next year's earnings per share (EPS) changes, investors can see the impact of the commercialization of the unique IL-15 therapy and patent protection, which confirms the fundamental resilience of the business in the face of competitors.